We can’t show the full text here under this license. Use the link below to read it at the source.
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibitor: A real‐world administrative database study in Japan
Reduced heart and metabolic risks in type 2 diabetes patients starting SGLT2 inhibitors compared to DPP-4 inhibitors in Japan
AI simplified
Abstract
The proportion of patients achieving a composite outcome was 31.0% for SGLT2 inhibitors compared to 12.9% for DPP4 inhibitors.
- Patients treated with SGLT2 inhibitors demonstrated a significantly higher rate of improvement in hemoglobin A1c, body mass index, and systolic blood pressure compared to those on DPP4 inhibitors.
- The risk difference for achieving the composite outcome was 18.6%, indicating a notable advantage for SGLT2 inhibitors.
- Treatment discontinuation was lower for SGLT2 inhibitor patients, with a hazard ratio of 0.85 suggesting better persistence in therapy.
- Both groups had balanced characteristics after matching, with 7,302 patients in each treatment category.
AI simplified
Key numbers
18.6%
Composite Outcome Achievement Increase
Proportion of patients achieving simultaneous reduction in HbA1c, BMI, and SBP.
0.85
Lower Treatment Discontinuation Risk
Hazard ratio for treatment discontinuation in SGLT2i vs. DPP4i groups.
7,302
Patient Cohort Size
Number of matched patients in each treatment group.